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Abstract
Background: In view of the long term discussion on the appropriateness of the dengue classification into dengue
fever (DF), dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS), the World Health Organization
(WHO) has outlined in its new global dengue guidelines a revised classification into levels of severity: dengue fever
with an intermediary group of “dengue fever with warning sings”, and severe dengue. The objective of this paper
was to compare the two classification systems regarding applicability in clinical practice and surveillance, as well as
user-friendliness and acceptance by health staff.
Methods: A mix of quantitative (prospective and retrospective review of medical charts by expert reviewers, formal
staff interviews), semi-quantitative (open questions in staff interviews) and qualitative methods (focus group
discussions) were used in 18 countries. Quality control of data collected was undertaken by external monitors.
Results: The applicability of the DF/DHF/DSS classification was limited, even when strict DHF criteria were not
applied (13.7% of dengue cases could not be classified using the DF/DHF/DSS classification by experienced
reviewers, compared to only 1.6% with the revised classification). The fact that some severe dengue cases could not
be classified in the DF/DHF/DSS system was of particular concern. Both acceptance and perceived user-friendliness of
the revised system were high, particularly in relation to triage and case management. The applicability of the revised
classification to retrospective data sets (of importance for dengue surveillance) was also favourable. However, the
need for training, dissemination and further research on the warning signs was highlighted.
Conclusions: The revised dengue classification has a high potential for facilitating dengue case management and
surveillance.
Background
Dengue is the most rapidly advancing vector-borne dis-
ease, with an estimated 50 million infections occurring
annually [1]. Its geographical spread has increased over
the years to now include most countries in the tropical
belt. The disease has shifted from a predominantly
paediatric disease to a disease affecting all age groups.
The understanding of dengue’s hallmark pathophysiol-
ogy has also changed; it is now recognized as plasma
leakage-related rather than haemorrhage-related. Thus,
the existing terminology - with its focus on haemor-
rhage - can be misleading for clinical management.
As dengue spreads worldwide, it has become evident
that the classification of the disease into DF, DHF
(Grades 1 and 2), and DSS (DHF Grades 3 and 4) [2]
may not be universally applicable for clinical manage-
ment [3-7]. In 2006, the WHO Dengue Scientific
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research on optimizing clinical management, in particu-
lar on the development and validation of dengue diag-
nostics and the analysis of new methods and guidelines
for triage and care of dengue patients.
A multi-centre study including a comparative analysis
of dengue clinical guidelines (DCG) from 13 countries
was carried out in 2009 to evaluate the variation in use of
the current DCGs in both Latin America and Asia [9].
The differences observed in the use of DCGs across
countries revealed in that study suggested a need to re-
evaluate and standardize dengue clinical guidelines, parti-
cularly dengue case classification and case management.
Within this context, data from a prospective clinical den-
gue study (DENCO) in 7 countries of South Asia and
Latin America served to optimize case detection and case
classification into non-severe and severe categories.
A series of regional and global expert meetings was
organized by the WHO-based Special Programme for
Research and Training (TDR) recognizing the evidence
for a classification of dengue disease into levels of clini-
cal severity [10], which was largely reconfirmed by the
findings of a later prospective-retrospective analysis [11].
The global expert meeting on dengue classification in
September 2008 in Geneva recommended a revised case
classification into dengue and dengue with warning
signs, and severe dengue (figure 1). This recommenda-
tion was based on (a) research evidence (from the
D E N C Os t u d y[ 1 0 ] )t h a ts h o w e dac l e a rd i s t i n c t i o n
between severe dengue and dengue criteria, as well as
on (b) expert opinion distinguishing between dengue
with and without warning signs. The definition of “den-
gue without warning signs” was largely based on the
dengue case definition of the previous WHO dengue
guidelines from 1997 [2]. The expert meeting recom-
mended further research related to (a) the applicability
and usefulness of the revised dengue classification (the
subject of the current paper) in comparison with the
DF/DHF Grades 1 and 2/DSS Grades 3 and 4 classifica-
tion, (b) the predictive value of warning signs for
patients who progressed to severe dengue (a multi-cen-
tre study to be started in 2010) and (c) an improved evi-
dence-based definition of “probable dengue” (to be
included in the predictive value study).
The study on usefulness and applicability of the
revised classification presented in this paper had the fol-
lowing objectives:
1. To analyse the revised dengue classification in
comparison to the DF/DHF 1 and 2/DSS 3 and 4
classification in relation to: (a) applicability in clini-
cal practice, (b) usefulness for triage and clinical
management, (c) user-friendliness and acceptance by
health staff.
2. To analyse the applicability of the revised classifi-
cation to retrospective data sets.
Methods
Study design and timelines
The study design, protocol and data collection instru-
ments were developed jointly through a communication
blog among 18 countries from four WHO regions (East-
ern Mediterranean Region (EMR), American Region
(AMR), South-East Asia Region (SEAR) and Western
Pacific Region (WPR). The participating countries were
located either in Latin America (12 countries) or Asia (5
countries plus one Eastern Mediterranean country).
Countries were selected in a competitive selection pro-
cess by an independent scientific committee. Unfortu-
nately two countries in the Mekong delta could finally
not take part due to administrative or financial reasons.
Tertiary and secondary hospitals, as well as health cen-
tres at primary care level, were included at each study
site.
The study was implemented from February to Novem-
ber 2009. A mixed methodology of quantitative and
qualitative data collection was used (see below).
Intervention method
Treatment algorithm and training A case management
algorithm was developed and pilot tested in the Philip-
pines. The case management algorithm guides the physi-
cian/nurse on what do in terms of diagnosis, treatment
and patient monitoring for each patient group (A, den-
gue without warning signs; B, dengue with warning
signs; and C, severe dengue) [1]. A standardized training
package consisting of two PowerPoint slide series about
diagnosis and case management according to levels of
severity was developed and agreed upon.
The revised dengue classification (figure 1) and the
case management algorithm were presented to dengue
physicians and nurses dealing with dengue patients in
each study site [primary health care (PHC) centres and
hospitals] during a day of standardised training at the
beginning of the study; the two series of PowerPoint
slides were used during this training. Physicians/nurses/
other healthcare personnel were also provided with wall
posters and flyers for their daily use.
Data collection and research methods Three to six
months after the initial training, health care personnel
were interviewed, while their use of the DF/DHF 1 and
2/DSS 3 and 4 and of the revised severity classification
was assessed through the analysis (by an experienced
clinician) of treatment charts (see below). In some sites
(with no or little inter-epidemic transmission of den-
gue), only retrospective analysis was performed (by
applying the case classification to existing data sets [2
nd
objective]). Figure 2 provides a list of the participating
countries and the timeframe of project activities.
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medical chart reviews (prospective and/or retrospective),
(2) self-applied questionnaires for health care personnel
and (3) focus group discussions (FGD) with health care
personnel.
Medical chart review Charts from previous years were
reviewed retrospectively while those that were started in
2009 (after the training was carried out in the institu-
tion) were reviewed prospectively. Reviewers were medi-
cal experts familiar with both the old and the revised
case classification. These experts were selected on the
basis of international recognition for their clinical exper-
tise in dengue management. One reviewer was responsi-
ble for Latin America and three for South-East Asia.
Prospective reviews were carried out after individual
patients had been discharged. Data was collected using a
detailed case report form (CRF) which included sections
on demographic information, clinical signs and symp-
toms, treatment, laboratory confirmation and outcome.
Participating clinicians followed their local standards for
the laboratory diagnosis of dengue; in some cases the
proportion of laboratory-confirmed dengue was high
and in others it was low (see discussion).
Self-applied staff questionnaires The staff question-
naire focused on the main issues surrounding the use of
current dengue guidelines (as shown in a recent analysis
of dengue guidelines [9]) and the recent experience of
staff when applying the revised dengue classification and
case management algorithm (compared to the DF/DHF/
DSS classification). Questionnaires in English or Spanish
(depending on the region) were distributed to 50 health-
care staff per facility (PHC units and/or hospitals) from
each site. The sample size was calculated to be a mini-
mum of 43 health care staff per facility from each site,
based on the hypothesis that at least 80% of staff (with a
precision of +/- 12% at a 95% confidence interval)
would report positive experiences with the revised clas-
sification. The questionnaires were filled by the staff
members themselves and handed back on the same day
to maximize participation.
Figure 1 The revised dengue case classification.( S o u r c e :D e n g u eG u i d e l i n e sf o rd i a g n o s i s ,t reatment, prevention and control, New edn.
Geneva: WHO; 2009)
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Page 3 of 12Focus Group Discussions with health staff Sample
individuals for focus group participation were selected
from two groups: (1) staff from health care facilities
(from primary to tertiary level, but not limited to the
public sector) in all study sites and (2) all available
health personnel dealing with dengue treatment (e.g.
health care workers, nurses, doctors, communicable dis-
ease control staff, epidemiologists and management
staff). A facilitator and an assistant visited each study
location according to scheduled appointments in order
to conduct the FGDs. Participants were reassured about
the confidentiality of any information they would give
and were asked to sign a consent form. No financial
incentives were given to the participants. The goal of
the FGD was explained: to assess staff experience and
level of comfort regarding the use of the revised case
classification system, the clinical management algorithm
and clinical guidelines compared to the DF/DHF 1 and
2/DSS 3 and 4 classification. Each discussion (duration
approximately 1-2 hours) was conducted in the local
language and covered a list of key topics. The discus-
sions were recorded using a standard cassette recorder
and information was transcribed at each individual site.
The information from all sites [12] was coded and clas-
sified according to categories that emerged from the
data [13]. The information was collapsed to allow for a
summary, and care was taken to disregard deviant state-
ments [14].
Data management and analysis
Quality control
Data monitoring was carried out in the study sites once
or twice during the study period by specially trained
external monitors who checked for correct application
of the study protocol and correct transfer of information
from the medical charts to the CRF. This ensured com-
parability of the data collected from each study site and
ensured that good clinical practices (according to stan-
dards) were applied.
Data management and analysis
Data were entered into the computer using a common
data entry programme EpiInfo. Data cleaning was first
done at country level. Data were then sent to the data
management centre at the University Hospital
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Figure 2 Timeline of training and completion of the different data collection instruments in the year 2009. ￿ as by last day of respective
activity. # only sites with prospective data
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Page 4 of 12Heidelberg in Germany, where the data sets were
merged into one database which was then analyzed
using STATA 9.2 (STATA Corporation, Duxbury, CA).
The focus group results were taped, transcribed and
analysed according to topic areas (categorical analysis).
Preliminary results were shared with participating coun-
tries in two regional meetings and public health mes-
sages were discussed. The final results were shared and
agreed by all the principal investigators from all of the
study sites.
Ethical clearance
Ethical approval was obtained from the WHO Ethical
Review Committee as well as from the local institutional
review boards at each study site. As mentioned,
informed consent was obtained from all study partici-
pants and information obtained from the subjects was
treated as confidential.
Results
Chart reviews
A total of 3248 medical chart reviews were received and
analysed from the 18 study sites. In Asia, 13% of the
charts were collected at PHC level, 33% at secondary
level and 54% at tertiary care level (in Singapore most
charts were collected at PHC level while in Indonesia
and Saudi Arabia most charts were collected at the sec-
ondary level). In Latin America, 30% of charts were col-
lected from primary level, 18% from secondary level and
49% from tertiary level (3% were missing or not deter-
mined). Chart reviews were carried out both prospec-
tively and retrospectively. Retrospective chart reviews
were applied to patient charts obtained from the time
period before the training course for the revised classifi-
cation/case management was initiated (N = 1156), and
prospective chart reviews were applied to charts which
were collected after the training course and analysed at
the end of the study period (N = 2092). The details are
presented in table 1. The following points are worth
being highlighted:
￿ Most countries performed both prospective and
retrospective chart reviews, and included staff inter-
views as well as FGDs.
￿ Three countries (North India, Singapore, Cuba)
where dengue shows a predominantly epidemic pat-
tern with little transmission in the inter-epidemic
periods applied the analysis exclusively to retrospec-
tive data sets. One country, Brazil, which was parti-
cularly interested in the use of the revised
classification in dengue surveillance, did the same.
Two countries (Singapore and Brazil) focused on the
retrospective analysis of existing data sets only and
did not include staff interviews.
￿ The mean age of dengue patients in the chart
reviews was dependent on the type of hospital/health
centre (paediatric or general).
￿ The laboratory confirmation of dengue was 58% on
average, being higher in Latin America (65%) than in
Asia (49%). Cases were considered laboratory-con-
firmed if positive either by PCR, by paired IgM,
paired IgG (acute and reconvalescent sera) or single
IgM tests.
Findings in the chart reviews
Completeness of information from routine practice to
classify dengue In order to analyse the applicability of the
“dengue with warning signs” category of the revised case
classification, the completeness of warning signs written in
routine medical charts (prospective and retrospective
assessments) were checked. These included: abdominal
pain or tenderness; persistent vomiting; clinical fluid accu-
mulation (e.g. clinical pleural effusion or ascites); bleeding
from mucosal surfaces; lethargy/restlessness; and liver
enlargement. In view of the DF/DHF 1 and 2/DSS 3 and 4
classification, it was evaluated whether peak and baseline
haematocrit and minimal platelet counts - which are
essential for diagnosing DHF - were available from routine
medical charts. It could be shown that:
￿ Where a prospective analysis was carried out,
potential warning signs were mentioned as being
present or absent in the majority of charts (93.1%;
1948/2092).
￿ In countries with mainly or exclusively retrospec-
tive analysis consistent information on warning signs
was not found in the charts.
￿ The tourniquet test - an important element in the
early diagnosis of DHF - was carried out in only
44.9% of the prospective patients (939/2092). This
was more frequent in Latin America (64.0%; 600/
937) than in Asia (29.3%; 339/1155).
￿ Both retrospective and prospective analysis
revealed that essential information for establishing
the DHF diagnosis was present only in a subset of
medical charts:
○ Tourniquet test: 55% (54% in retrospective;
55% in prospective)
○ Hematocrit (maximum): 11% (9% in retrospec-
tive; 12% in prospective)
○ Hematocrit (baseline): 53% (54% in retrospec-
tive, 52% in prospective)
○ Fluid accumulation: 30% (35% in retrospective;
27% in prospective)
○ Thrombocytopenia: 6% (6% in retrospective;
6% in prospective)
Applicability of the DF/DHF/DSS and revised classifi-
cation to prospective data sets As mentioned earlier,
all medical charts completed by the treating physician
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only the 2092 charts with prospective data were
included. Four hundred and sixty-two of these patients
referred to in these charts had manifestations of bleed-
ing (22.1%; 462/2092); and 7.7% (162/2092) had shock
according to the clinical definition. After excluding
charts with missing values, 1962 of the patient charts
were included in the following analysis (Table 2).
In terms of applicability, the revised classification cap-
tured more cases than the DF/DHF 1 and 2/DSS 3 and
4 classification, as 13.7% (268/1962) of dengue patients
could not be classified in the DF/DHF/DSS system
because of missing information while only 1.6% (32/
1962) of patients could not be classified in the revised
system.
A cross-tabulation (see table 2) shows how the cate-
gories of the DF, DHF grade 1 and 2, DSS grade 3 and
4 classification match the categories of the revised clas-
sification (dengue and severe dengue). According to the
judgment of the expert reviewer, DF cases were spread
over different severity categories in the revised classifica-
tion: 5.7% of DF cases were actually classified as “severe
dengue” and 93.7% of DF cases were classified as “den-
gue” (with 41.8% of DF cases in the “dengue -WS” cate-
gory and 51.9% in the “dengue +WS” category). A high
proportion of DHF cases were also classified as “dengue”
by the expert reviewer, 83% of which fell in the “dengue
+WS” category. Most DSS cases (86.4%) were classified
in the “severe dengue” category; however 12 DSS cases
were found in the “dengue” group (all of them in the
“dengue +WS”). Detailed analysis showed that only one
of these 12 DSS cases had actual shock, but that all 12
had warning signs (as listed in the revised classification)
and hence were correctly classified as “dengue with
warning signs”. Patients with shock (according to the
clinical definition of pulse pressure below 20 mm Hg
and/or hypotensive for age) account for 7.7% (N = 162/
2092) of the total in the prospective chart reviews. Only
60 of these (37.0%) were classified as DSS but 145
(89.5%) were classified as “severe dengue”, underlining
the difficulty of applying the DSS definition (which is
linked to DHF criteria). Thrombocytopenia was present
and documented in 106 cases (72%), and bleeding ten-
dency/tourniquet test was positive in 97 cases (60%) of
Table 1 Number of staff questionnaires (Q), focus group discussions (FGD) and chart reviews by country/hospital site
Country N Staff
Q
N
FGDs
Chart Reviews
N (m/f*) Prospective review (% of all charts)
**
Mean age
(SD)
laboratory-
confirmed
India 54 7 148 (106/42) 0 29 (14.4) 146 (99%)
Indonesia 115 6 389 (207/182) 303 (78%) 16 (10.8) 98 (25%)
Malaysia 92 5 353 (233/120) 336 (95%) 26 (14.4) 234 (66%)
Philippines 101 18 347 (174/173) 337 (97%) 14 (9.0) 0 (0)
Singapore 0 0 103 (60/43) 0 40 (14.2) 103(100%)
Saudi Arabia 187 6 299 (164/35) 179 (90%) 31 (13.0) 174 (87%)
Asia subtotal 549 42 1539 (944/959) 1155 (75%) 23 (14.6) 755 (49%)
Bolivia 137 5 256 (115/141) 194 (76%) 23 (15.3) 142 (55)
Brazil 0 0 94 (46/48) 0 37 (18.6) 93 (99)
Colombia 21 0 141 (68/73) 76 (54%) 14 (16.0) 59 (42)
Cuba 38 3 100 (39/61) 0 26 (19.3) 98 (98)
El Salvador 90 3 60 (30/30) 60 (100%) 8 (6.1) 56 (93)
Ecuador 70 4 72 (42/30) 54 (75%) 24 (18.9) 60 (83)
Mexico 58 0 38 (22/16) 38 (100%) 34 (19.2) 21 (55)
Nicaragua 108 2 528 (267/261) 346 (66%) 9 (6.9) 475 (90)
Paraguay 111 3 92 (36/56) 13 (14%) 36 (19.2) 46 (50)
Peru 80 0 117 (63/54) 39 (33%) 26 (16.4) 21 (18)
Puerto Rico 9 4 58 (30/28) 42 (72%) 27 (19.1) 31 (53)
Venezuela 17 5 153 (75/78) 75 (49%) 12 (11.3) 12 (8)
Latin America
subtotal
739 29 1709 (833/876) 937 (55%) 19 (17.0) 1114 (65%)
Grand Total 1288 71 3248 (1777/
1471)
2092 (64%) 21 (16.0) 1869 (58%)
* m/f: male/female ratio; ** all charts include retrospective and prospective reviews
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Page 6 of 12patients with shock. Eleven patients (7%) did not exhibit
either thrombocytopenia or bleeding tendency.
A high percentage of the severe dengue cases accord-
ing to the revised classification were lab confirmed (183
of 219; 70.3%) - including those classified as DF by the
expert reviewer (71 of 75). The majority of these cases
was treated in a tertiary hospital (64 of 75) or came
from Nicaragua (65 out of 75).
Out of the 684 patients classified as DF by the current
classification and “dengue +WS” by the revised classifi-
cation (see table 2), 54.4% were laboratory confirmed,
61.7% came from Asia, and 58.5% were treated at a ter-
tiary care facility.
Out of the 8 patients classified as DHF by the current
classification and “dengue - WS” by the revised classifi-
cation (see table 2), 7 were lab confirmed; they are dis-
tributed over different countries - mostly in Latin
America - and were treated in secondary as well as ter-
tiary care facilities (4/4).
Applicability of the DF/DHF/DSS and revised classifi-
cation to retrospective data sets Eleven thousand and
fifty-six charts were included in the retrospective analy-
sis, of which 850 had complete information. The analy-
sis showed similar results to the prospective assessment:
￿ A substantial proportion of cases (12.5%; 106/850)
could not be classified with the DF/DHF/DSS system
and a small proportion (3.1%; 26/850) could not be
categorized with the revised classification system. A
high proportion of non-classifiable cases with DF/
DHF/DSS belonged to the category “severe dengue”
under the revised classification system (32.1%; 34/
106).
￿ DF and DHF were spread over the 3 severity levels
of the revised system (examples: 81.9% of 116 DHF
cases were “dengue +WS” and the reminder in the
other two categories; 47.1% of 610 DF cases were
under “dengue -WS” and 47.5% under “dengue
+WS”).
￿ As in the prospective analysis, a small proportion
of DSS cases (16.7%; 3/18) was not classified as
“severe dengue” but as “dengue +WS” and in fact
did not fulfil the shock criteria.
Staff opinion about the DF/DHF/DSS, revised case
classification and treatment algorithm expressed in
written interviews
Characteristics of respondents and availability of dengue
guidelines
One thousand two-hundred eighty-eight staff question-
naires were obtained in 16 study countries; 549 in Asia
and 739 in Latin America. Most respondents were clini-
cians (74.1% of all respondents; N = 954) or nurses
(21.8% of all respondents; N = 281). The proportion of
nurses was similar at primary, secondary and tertiary
level, but the proportion of clinicians was particularly
high at tertiary level (80.6% of all respondents at tertiary
level; N = 602).
Of all respondents, 90.8%; N = 1169) had experience
in dengue care in their current position (91.8% in Asia
and 90.1% in Latin America). Most respondents had
received some kind of clinical training in dengue (on
average 63.1%; 48.6% in Asia and 73.9% in Latin Amer-
ica). Forty-two percent of all respondents had been
working with dengue patients for 1 to 5 years, 27% for
more than 5 years, and 23.7% for less than one year.
More than half of all the respondents (55.4%) had seen
less than 50 patients in the previous year, while 24.7%
had seen more than 50 patients and 7.7% had seen
none.
The most common source of dengue clinical guide-
lines were Ministries of Health (68.4%), followed by
WHO Regional Offices (59.9%) and health facilities
themselves (30%).
Table 2 Comparison of the current (DF/DHF/DSS) and the revised classification in 1962 prospective chart reviews (130
charts with missing information excluded)
DF/DHF/DSS classification by expert reviewer Revised classification by expert reviewer Total
Not classifiable Dengue Severe Dengue
WS negative WS positive
Not classifiable 23
(8.6%)
57
(21.3%)
159
(59.3%)
29
(10.8%)
268 (100%)
(13.7% of all)
DF 7
(0.5%)
551
(41.8%)
684
(51.9%)
75
(5.7%)
1317 (100%)
(67.1% of all))
DHF (grades 1 and 2) 2
(0.7%)
8
(2.8%)
240
(83.0%)
39
(13.5%)
289 (100%)
(14.7% of all)
DSS (DHF grades 3 and 4) 0
(0%)
0
(0%)
12
(13.6%)
76
(86.4%)
88 (100%)
(4.5% of all)
Total 32
(1.6%)
616
(31.4%)
1095
(55.8%)
219
(11.2%)
1962 (100%)
* not classifiable = classification was not possible
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Sixty-five percent of respondents (843/1288) stated that
they had used the revised classification. Of these, 83.3%
(95% CI: 80.6-85.7) found the current guidelines with
the DF/DHF/DSS system useful and 96.1% (95% CI:
94.5-97.3) found the revised classification useful. In
Asia, 90.4% (95% CI: 87.1-93.1) of respondents were
satisfied with the DF/DHF/DSS system and 96.6% (95%
CI: 94.3-98.1) with the revised classification. In Latin
America, 76.7% (95% CI: 72.4-80.5) of respondents
found the DF/DHF/DSS system useful and 95.7% (95%
CI: 93.3-97.4) considered the revised classification to be
useful. Differences of opinion on the two classification
systems were statistically significant.
The following sections about staff opinions regarding
the revised classification and treatment algorithm show
many similarities with the results obtained by the FGDs.
In order to avoid repetition, and to facilitate the over-
view of answers given, a table with examples of answers
from the staff questionnaires and FGDs is available
under additional file 1.
Positive and negative opinions regarding the revised case
classification
Table 3 provides a summary of staff opinions regarding
the perceived advantages and disadvantages of the
revised case classification; 75.9% are positive while
24.1% had negative comments.
When specifically asked for negative experiences with
the revised classification, only 20 respondents (4% of all)
responded with specific comments, mainly pertaining to
the wide range of warning signs and symptoms, symp-
toms being vague and also associated with other dis-
eases, and the absence of shock syndrome not alerting
the treating doctor.
When asked if the revised classification is useful for
the classification and triage of patients compared to the
DF/DHF/DSS classification, the most frequent answers
were that (a) it simplifies case management and leads to
adequate treatment (N = 162), (b) it allows for a more
precise dengue classification including severity (N = 97),
and (c) it is simpler, more practical and user friendlier
(N = 91).
Staff opinions regarding the treatment algorithm based on
the revised case classification
Six hundred and ninety-eight comments were received
regarding the applicability of the treatment algorithm;
83% were positive about the algorithm. However, the
remaining responses (17%) referred to the lack of staff
to apply the guidelines, poor training, difficulty in acces-
sing the documents (in Latin America only), and una-
vailability of diagnostic tests.
When asked for recommendations regarding the
extended use of the treatment algorithm across coun-
tries and continents, there was a feeling that more train-
ing and dissemination of the revised classification and
treatment algorithm were needed (53.4% out of 698
responses). Respondents also suggested better access to
diagnostic tests (20.2%), better training (38.7%) and the
need for more concise parameters for treatment inter-
ventions (18.2%).
Staff opinion about the DF/DHF/DSS classification, revised
case classification and treatment algorithm expressed in
Focus Group Discussions
Thirteen countries held 71 FGD in total. Personnel from
75 health care facilities attended. The participants in the
focus groups - mostly medical staff and nurses involved
in dengue care, but also in some cases epidemiologists
and public health staff - had received training about the
revised dengue case classification and treatment algo-
rithm 3 to 6 months before the FGD. Observer bias was
reduced by tape recording of the interviews with subse-
quent transcription and categorical analysis (see
methods).
Staff perceptions about (a) positive and (b) negative
aspects of the revised classification as well as about (c)
applicability of the treatment algorithm (based on the
revised classification) and staff recommendations will be
presented:
Table 3 Perceived advantages and disadvantages
regarding the revised dengue case classification
(N = 1413 comments in 1288 staff questionnaires)
Advantages of the revised classification N (%)
It helps improving management and treatment 319
(22.6%)
More simple and practical 199
(14.0%)
Easier to classify according to severity 176
(12.6%)
Easier to understand 71 (5.0%)
It helps improving triage and referral 45 (3.2%)
No disadvantages of the revised classification 191
(13.5%)
Other advantages 72 (5.0%)
Total of positive responses 1073
(75.9%)
Disadvantages of the revised classification N (%)
No advantages of the revised classification 25 (1.8%)
Needs more training and dissemination 67 (4.7%)
It’s less specific. Needs more clinical entities and concise
protocols
54 (3.8%)
Lack of manpower and resources 45 (3.2%)
Over diagnosis of dengue (saturation of hospitals) 32 (2.3%)
Warning signs: Too many, subjective, also in other diseases 24 (1.7%)
Lack of laboratory support 10 (0.7%)
Other disadvantages 83 (5.9%)
Total of negative responses 340(24.1%)
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Across all study sites, the revised case classification
received positive comments, particularly regarding its
ease of use and focus on clinical management: “The
revised case classification is very practically oriented,
didactic, has a good and clear scheme, is easy and clear”
(Bolivia). Advantages were frequently mentioned: “The
term hemorrhagic has been generally misunderstood”
(Philippines), the “...epidemiological profile can now be
better described” (Cuba/Ecuador), “The classification
reflects the dynamic changes of the disease” (India), there
is “...a reduced need for laboratory testing” (Paraguay),
and the “...incorporation of warning signs...” is perceived
to be useful for clinical management (El Salvador).
Comments from epidemiologists involved in the FGD
were equally positive: “For epidemiologists and surveil-
lance officers, the revised guidelines will be able [sic] to
establish consistency of data entries for both hospital
statistics and morbidity/mortality rates” (Philippines).
In all sites, there was a general view that the revised
case classification is better for case management and
triage compared to the DF/DHF/DSS system.
b) Perceived limitations of the revised classification
Some concerns were raised about the use of the revised
classification system. These were site specific and not as
general as the positive comments:
￿ One of the difficulties will be the need for staff
training in the introduction phase of the revised
classification.
￿ “T h e r em a yb ean e e df o rl o c a la d a p t a t i o no fs o m e
elements” (Cuba/Ecuador).
￿ “23 out of 40 participants would not consider the
increasing haematocrit with decreasing platelet count
as a warning sign, but rather it should be deferves-
cence” (Philippines).
￿ “Initially we thought to have more admissions but
this was not the case” (Malaysia).
￿ Epidemiological data collection needs to be
updated and the surveillance system needs to be
adapted.
c) Applicability of the treatment algorithm
In most countries, no algorithm for triage and dengue
case management existed prior to this study. Therefore,
most medical staff welcomed the decision-making algo-
rithm as practical support. Positive comments (across all
sites in Latin America and Asia) highlighted the advan-
tages of having clear triage criteria (especially with
warning signs), the reduced requirement of laboratory
testing, the compatibility with the concept of Integrated
Management of Childhood Illness and the recognition
of social factors. For example in the Philippines: “All of
the 40 participants said that the algorithm is simple and
easy to follow and is very useful in triaging patients,
classifying dengue and therefore managing the disease”,
or in Puerto Rico where immediate action was taken:
“Previously existing guidelines are already updated to
include the revised case classification”, or in Colombia:
“The advantage I can see is the clear link between classi-
fication and case management”.
Some concerns were related to the following issues:
￿ The introduction of change is always difficult and
will require extra efforts in the implementation.
￿ In countries with existing treatment flowcharts
(algorithms) including cut-off level of 100,000 plate-
lets, this was also perceived to be useful for deci-
sion-making.
￿ Harmonization between different existing guide-
lines is needed, since there are different WHO,
regional and national guidelines circulating (The
Philippines).
￿ In high endemicity countries, the unrestricted use
of warning signs may lead to unnecessary admissions
(Indonesia).
Discussion
The present study used a methodological mix of quanti-
tative, semi-quantitative and qualitative methods to
determine the applicability of the revised dengue case
classification system in 18 countries. Efforts were made
to reduce observer bias and ensure robustness of data as
discussed below.
Applicability of a dengue classification system in the
clinical practice (objective 1)
The limited applicability of the DF/DHF Grade 1 and
2/DSS Grades 3 and 4 classification in clinical practice
(particularly at PHC level), due to the rigidity of classi-
fication criteria and dependence on laboratory tests,
has been highlighted in literature reviews [6]. The pro-
spective clinical DENCO study [10] further showed
that in ~18% of dengue cases a correct application of
the DHF criteria (fever, hemorrhagic tendencies,
thrombocytopenia and plasma leakage expressed as
raising haematocrit, pleural effusion and other signs
and symptoms) was not possible. This has apparently
lead to the clinical practice of diagnosing DHF without
all the necessary criteria and the application of locally
adapted variations [9]. Our study highlights these
issues. A large proportion - usually above 50% - of
DHF criteria (such as haematocrit before and after
treatment, platelet counts, and tourniquet tests), were
not collected by the clinician; however, the expert
reviewer of the medical charts used clinical judgement
to come to the DHF diagnosis. But even doing so,
13.7% of patients could not be classified into the DF/
DHF/DSS categories.
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could not be classified and the warnings signs for severe
disease (necessary for the “dengue +WS” category) were
documented in a large proportion of medical charts (see
the section on “completeness of information” in the
results).
The revised classification also proved to be more sen-
sitive for timely recognition of severe disease. Prospec-
tive chart reviews across all three levels of the health
care system showed that a significant proportion of
cases classified as DF by the DF/DHF 1 and 2/DSS 3
and 4 classification are picked up as potentially severe
or severe (dengue plus warning signs or severe dengue)
by the revised classification. In a direct comparison of
the two classification systems, 51.9% (684/1327) of the
DF cases were classified as dengue plus warning signs
(revised classification) and another 5.7% (75/1327) as
severe dengue (revised classification). Mismatches in the
other direction, where cases were actually classified
more severe by the DF/DHF 1 and 2/DSS 3 and 4 com-
pared to the revised classific a t i o n ,w e r eo n l yp r e s e n ti n
a very small proportion, most of them being cases of
DHF that were classified as “dengue without warning
signs” according to the revised classification (N = 8,
according to expert reviewer).
Applicability of a dengue classification system in dengue
surveillance (retrospective chart review (objective 2)
The difficulties of applying the DF/DHF/DSS system in
dengue surveillance are documented [6]. In this study,
the applicability of the two classification systems to ret-
rospective data sets was tested. Here again the propor-
tion of “non-classifiable” cases was higher when
applying the DF/DHF/DSS system (12.5%) than when
applying the revised case classification (only 3.1%). It is
of particular concern that 32.1% of severe dengue cases
could not be classified in the DF/DHF/DSS system. The
completeness of information, particularly on potential
warning signs, was lower in the retrospective chart
review than in the prospective one - contributing to the
3.1% which could not be classified.
Usefulness of a severity classification for triage and case
management (objective 1)
During an outbreak simple criteria for triage and case
management are required to decide if patients can be
treated at home, in a hospital ward or require intensive
care. During inter-epidemic periods, endemic or spora-
dic transmission remains and triaging dengue cases for
case management remains important for organizing
health services. Our study is in line with the findings of
t h ep r o s p e c t i v eD E N C Os t u d yt h a tD F ,D H Fa n dD S S
only match to a limited degree with a more clinically
oriented classification of severity. The revised
classification was easily applicable in clinical practice
(see above) but was also seen to be useful for triage and
case management by medical staff, more frequently than
the DF/DHF/DSS classification.
Yet, in the focus groups and questionnaires, some
concerns on the revised classification were raised, these
included:
￿ hospitalization rates might increase if the warning
s i g n sa r en o tp r e c i s e l yd e f i n e da n dt h e r e f o r et h e
need for a prospective study on the definition and
usefulness of warning signs across different countries
and health care levels was emphasized
￿ cost implications if more patients are being
admitted
￿ the need for more training and dissemination and
for more concise clinical protocols
The question if the revised classification leads to
higher patient numbers cannot be answered with the
results from this study and remains to be clarified.
Issues related to triage and case management will have
to be addressed in future studies.
Potential bias/limitations
The term prospective vs. retrospective refers to the tim-
ing of the training versus the treatment of the patients
by the treating physician. Reviewers’ assessment of the
patient’s classification was based on the medical chart
after discharge of the patient. Thus, the knowledge of
the outcome could theoretically have influenced the
reviewer’s assessment. However, as the reviewer had to
check the presence of one or more items to classify
severe dengue (revised classification) or a set of four
items for DHF (current classification) the potential bias
would most probably have worked in favour of the cur-
rent classification in the sense that cases with severe
clinical course would receive special attention to investi-
gate the presence of all items needed to fulfil DHF in
case of the old classification.
Acceptance and user-friendliness of a dengue
classification system (objective 1)
Staff interviews and FGDs suggested that the level of
acceptance for the revised classification was high. This
was particularly the case for Latin America. Surprisingly
it was also high in Asia, where the DF/DHF/DSS classi-
fication has a long tradition [15,16].
The staff questionnaires also revealed that the revised
classification was perceived as being more user-friendly
compared to the DF/DHF/DSS classification, and that this
has a direct implication on adequate case management
and treatment. The respondents appreciated the revised
classification with its emphasis on clinical severity which
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the clinical management algorithm. There was also an
agreement across countries and through all methods used
that the use of warning signs for case management, as
reflected in the revised classification, is of practical value.
However, it is obvious that both the definition of “warning
signs for severe dengue” and the predictive value of these
signs require further research. In addition, the question of
a (clinical) dengue case definition in the absence of confir-
matory laboratory tests needs further research. Taking
into account the lessons learned from development of the
revised classification, the development and dissemination
of detailed guidelines on dengue clinical management is
crucial - with emphasis placed on training for health staff
at all levels. Furthermore, as suggested in a number of
staff interviews, the recognition of special situations
such as dengue in pregnancy, dengue and co-morbidities,
dengue in paediatric and adult care need further
consideration.
While there is a need for harmonizing guidelines (see
[9]), it also may well be that algorithms in the dengue
case definition may vary from region to region or even
from country to country, and that some warning signs
for severe dengue may show geographical variation. This
will require the adaptation of dengue clinical guidelines
to local characteristics. However, this study has shown
that the revised dengue classification is suitable for clini-
cal practice. For dengue surveillance, there is potential
f o rt h er e v i s e dc l a s s i f i c a t i o nt ol e a dt os i m p l e r ,m o r e
consistent, and comparable data on dengue and severe
dengue.
Conclusions
The revised dengue classification has a high potential for
facilitating dengue case management and surveillance. It
was shown and perceived to be more sensitive than the
DF/DHF/DSS classification for timely recognition of
severe disease. Both acceptance and perceived user-
friendliness of the revised system were high, particularly
in relation to triage and case management. The applic-
ability of the revised classification to retrospective data
sets was also favourable and the proportion of non-clas-
sifiable cases overall was very low.
The need for training and dissemination in general,
and for further research on warning signs and on the
clinical case definition of dengue in the absence of
laboratory testing in particular, was highlighted.
Additional material
Additional file 1: Overview table of opinions regarding revised
dengue classification and treatment algorithm
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